Literature DB >> 32052568

Tetra positive thrombotic antiphospholipid syndrome: Major contribution of anti-phosphatidyl-serine/prothrombin antibodies to lupus anticoagulant activity.

Maria Grazia Cattini1, Elisa Bison1, Elena Pontara1, Chunyan Cheng1, Gentian Denas1, Vittorio Pengo1.   

Abstract

BACKGROUND: The concurrent presence of lupus anticoagulant, anticardiolipin, and anti β2-glycoprotein I antibodies (triple positive profile) identifies patients at high risk of thromboembolic events. These patients are also positive for anti-phosphatidyl-serine/prothrombin antibodies (tetra-positive profile).
OBJECTIVE: Understand which antibody among anti-β2-glycoprotein I and anti-phosphatidyl-serine/prothrombin is responsible for lupus anticoagulant activity. PATIENTS/
METHODS: Affinity purified anti-β2-glycoprotein I antibodies from plasma of 14 tetra-positive patients spiked into normal pooled plasma were tested. RESULTS AND
CONCLUSIONS: Anti-β2-glycoprotein I antibodies did not prolong the diluted Russell viper venom time and silica clotting time (median ratio 0.98, interquartile ratio [IQR] 0.9-1.06; and 1.0, IQR 0.91-1.03, respectively). Anticoagulant activity remained in the flow-through that was deprived of anti-β2 glycoprotein I antibodies (median ratio 1.88, IQR 1.58-2.77; and 1.75, IQR 1.17-2.9, respectively). This material was loaded on size-exclusion chromatography Sephacryl S-300 column and showed that anticoagulant activity and anti-phosphatidyl-serine/prothrombin antibodies coeluted in the same fractions. Besides, the flow through was poured into a prothrombin affinity column. Protein yield in three patients ranged from 54 to 91 μg/mL and showed strong positivity in phosphatidyl-serine/prothrombin ELISA. The affinity purified material prolonged the coagulation time of normal pooled plasma: the diluted Russell viper venom ratio in the three patients was 2.09, 1.21, and 1.35; that of silica clotting time was 2.05, 1.5, and 2.13. In conclusion, under the assay conditions used, anticoagulant activity in tetra-positive antiphospholipid syndrome patients may largely be attributable to anti-phosphatidyl-serine/prothrombin antibodies.
© 2020 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  antibodies; lupus anticoagulant; prothrombin; thrombosis; β2-glycoprotein I

Mesh:

Substances:

Year:  2020        PMID: 32052568     DOI: 10.1111/jth.14765

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  5 in total

Review 1.  Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances.

Authors:  Arne Vandevelde; Katrien M J Devreese
Journal:  J Clin Med       Date:  2022-04-13       Impact factor: 4.964

2.  Associations with thrombosis are stronger for antiphosphatidylserine/prothrombin antibodies than for the Sydney criteria antiphospholipid antibody tests in SLE.

Authors:  Sahwa Elbagir; Giorgia Grosso; NasrEldeen A Mohammed; Amir I Elshafie; Elnour M Elagib; Agneta Zickert; Vivek Anand Manivel; Eleftheria Pertsinidou; Musa A M Nur; Iva Gunnarsson; Johan Rönnelid; Elisabet Svenungsson
Journal:  Lupus       Date:  2021-05-06       Impact factor: 2.911

3.  Anti-β2-glycoprotein I and anti-prothrombin antibodies cause lupus anticoagulant through different mechanisms of action.

Authors:  Tessa Noordermeer; Jessica E Molhoek; Roger E G Schutgens; Silvie A E Sebastian; Sandra Drost-Verhoef; Annet C W van Wesel; Philip G de Groot; Joost C M Meijers; Rolf T Urbanus
Journal:  J Thromb Haemost       Date:  2021-02-09       Impact factor: 5.824

Review 4.  Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants.

Authors:  Emmanuel J Favaloro; Leonardo Pasalic
Journal:  Res Pract Thromb Haemost       Date:  2022-03-15

5.  Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome.

Authors:  Maria Orietta Borghi; Asmaa Beltagy; Emirena Garrafa; Daniele Curreli; Germana Cecchini; Caterina Bodio; Claudia Grossi; Simonetta Blengino; Angela Tincani; Franco Franceschini; Laura Andreoli; Maria Grazia Lazzaroni; Silvia Piantoni; Stefania Masneri; Francesca Crisafulli; Duilio Brugnoni; Maria Lorenza Muiesan; Massimo Salvetti; Gianfranco Parati; Erminio Torresani; Michael Mahler; Francesca Heilbron; Francesca Pregnolato; Martino Pengo; Francesco Tedesco; Nicola Pozzi; Pier Luigi Meroni
Journal:  Front Immunol       Date:  2020-10-15       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.